Oncogenes and angiogenesis: Signaling three-dimensional tumor growth

Journal of Investigative Dermatology Symposium Proceedings

Volumn 5, Issue 1, 2000, Pages 24-33

  Rak, Janusz ^a   Yu, Joanne L ^a   Klement, Giannoula ^a   Kerbel, Robert S ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Anoikis; Apoptosis; Cancer thrombospondin; Ras; Vascular dependence; VEGF

Indexed keywords

PROTEIN C FOS; PROTEIN P16; PROTEIN P53; RAS PROTEIN; THROMBOSPONDIN 1; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; CELL GROWTH; CELL SURVIVAL; CONFERENCE PAPER; DOWN REGULATION; HUMAN; MALIGNANT TRANSFORMATION; MITOGENESIS; ONCOGENE; ONCOGENE C MYB; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE RAS; ONCOGENE SRC; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0034502557     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1087-0024.2000.00012.x     Document Type: Article

References (142)

1. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription
2. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
3. Human omithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice
4. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
5. Inhibition of apoptosis during development of colorectal cancer
6. Up-regulation of vascular endothelial growth factor production by iron chelators
7. Myb-dependent regulation of thrombospondin 2 expression
8. Cancer: The rise of the genetic paradigm
9. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy
10. Non-nuclear oncogenes and the regulation of gene expression in transformed cells
11. How tumors become angiogenic
12. Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents
13. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
14. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
15. Activated H-ras transforms rat intestinal epithelial cells with expression of α-TGF
16. Intussusceptive microvascular growth, a new mechanism of capillary network expansion
17. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
18. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
19. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene
20. Ras-responsive genes and rumor metastasis
21. The upregulation of vascular endothelial growth factor in mutated Ha- ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor
22. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
23. Essential role for oncogenic Ras in tumour maintenance
24. Expression of vascular permeability factor/vascular endothelial growth factor melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
25. Human cutaneous malignant melanoma as a model for cancer
26. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
27. Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/osteopontin: Enhanced expression in H-ras-transformed 3T3 cells
28. Expression of ras oncogenes in cultured human cells alters the transcriptional posttranscriptional regulation of cytokine genes
29. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements
30. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene
31. Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells
32. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer
33. Down-regulation of vascular endothelial growth factor in human colon carcinoma cell lines by antisense transfection decreases endothelial cell proliferation
34. A genetic model for colorectal tumorigenesis
35. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects
36. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras
37. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
38. The biology of vascular endothelial growth factor
39. Tumor angiogenesis
40. What is the evidence that tumors are angiogenesis-dependent?
41. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, minor vascularization, and growth of multiple tumor types
42. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
43. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells
44. mAngiogenin-3, a target gene of oncoprotein E2a-Pbx 1, encodes a new angiogenic member of the angiogenin family
45. Tumor induction of VEGF promoter activity in stromal cells
46. Altered regulation of TGF-beta 1 and TGF-alpha in primary keratinocytes and papillomas expressing v-Ha-ras
47. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
48. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
49. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
50. Tumor derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function
51. Effect of novel Caax peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo
52. Proliferation of human malignant astrocytomas is dependent on Ras activation
53. Creation of human tumour cells with defined genetic elements
54. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
55. The hallmarks of cancer
56. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas
57. K-ras gene mutations in early colorectal cancer, flat elevated vs polyp-forming cancer
58. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
59. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression
60. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
61. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice
62. Oncoprotein networks
63. Purification of 18- and 22-kDa forms of basic fibroblast growth factor from rat cells transformed by the ras oncogene
64. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
65. Vascular and interstitial barriers to delivery of therapeutic agents in tumors
66. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells
67. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha, Modulation of transcriptional activity by oxygen tension
68. A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression
69. Establishing a link between oncogenes and tumor angiogenesis
70. Translational regulation of vascular permeability factor byeukaryotic initiation factor 4E: Implications for tumor angiogenesis
71. The Ras signal transduction pathway
72. Increasing complexity of Ras signal transduction: Involvement of Rho family proteins
73. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
74. Continuous low-dose therapy with vinblastine and VEGF receptor- 2 antibody induces sustained tumor regression without toxicity
75. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
76. Regulation of vascular endothelial growth factor expression in human colon cancinoma cells by cell density
77. HPV- 16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes
78. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia
79. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene
80. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
81. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT
82. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry
83. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro
84. The involvement of activated ras genes in determining the transformed phenotype
85. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
86. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma
87. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras- transformed cells through a hypoxia inducible factor-1 transcriptional element
88. Vasculogenic mimicry: How convincing, how novel, and how significant?
89. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression
90. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma
91. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts
92. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
93. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
94. Cellular interactions in metastasis
95. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas
96. MTS1/p16/CDKN 2 lesions in primary glioblastoma multiforme
97. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression·
98. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation
99. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
100. Impact of oncogenes on tumor angiogenesis: Mutant K-ras upregulation of VEGF/VPF is necessary but not sufficient for tumorigenicity of human colorectal carcinoma cells
101. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: Effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts
102. Tumor related angiogenesis
103. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion
104. Anti-epidermal growth factor receptor antibody C 225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
105. Oncogenes as inducers of tumor angiogenesis
106. Reciprocal paracrine interactions between tumor cells and endothelial cells. The 'angiogenesis progression' hypothesis
107. Treating cancer by inhibiting angiogenesis: New hopes and potential pitfalls
108. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
109. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: Suppression by expression of a mutant c-Hras oncogene
110. Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis
111. Oncogenes and tumor angiogenesis: Differential modes of vascular endothelial growth factor up-regulation in rastransformed epithelial cells and fibroblasts
112. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1alpha
113. Cyclins. Cdks, and cyclin kinase inhibitors
114. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic as pathway in vivo
115. Downregulation of Bak plays a critical role in the growth of the ras-induced malignant phenotype in intestinal epithelial cells
116. c-fos is required for malignant progression for skin tumors
117. Inhibition of growith of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
118. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to elF- 4E
119. Inhibition of rasinduced proliferation and cellular transformation by p 161NK4
120. Oncogenic ras provokes premature cell senescence associated with accumulation of p 53 and p161NK4a
121. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
122. Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells
123. Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF)
124. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
125. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie- 2 pathway
126. Transformation by v-src causes transient induction followed by repression of mouse thrombospondin-1
127. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
128. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
129. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour
130. The histological structure of some human lung cancers and the possible implications for radiotherapy
131. The human gene for vascular endothelial growth factor
132. Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg. AC transgenic mice and FVB/N mice
133. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
134. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
135. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
136. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
137. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
138. Heterogeneous vascular dependency of tumor cell populations
139. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines
140. Maspin is an angiogenesis inhibitor
141. A genome-wide survey of RAS transformation targets